Menu

Gracell Biotechnologies Announces Shareholders’ Approval of Merger Agreement

February 20, 2024

Week In Review: Shanghai Inmagene Signs $230 Million Deal To Develop Two HutchMed Immunology Assets ↗

Gracell Biotechnologies Inc. (NASDAQ: GRCL) is a Stock Spotlight on 2/7

February 07, 2024

Via Investor Brand Network

Health Care Company AstraZeneca Announces Acquisition of Gracell Biotechnologies ↗

December 26, 2023

Via Benzinga

February 03, 2024

Inmagene Biopharma of Shanghai transferred 7.5% of its shares to HutchMed for global rights to two clinical stage immunology assets. It will also be responsible for up to $230 million in milestones.

Via Talk Markets

Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple Myeloma

January 29, 2024

Further expands clinical development of FasTCAR-T GC012F in multiple myeloma amid ongoing U.S. trial evaluating therapy for treatment of relapsed/refractory multiple myeloma

Focus On Bristol Myers, Gilead Sciences, Johnson & Johnson, Novartis: FDA To Issue Classwide Black Box Warning on CAR-T Therapies For Blood Cancer Treatment ↗

January 23, 2024

In a significant development, the FDA is set to impose a classwide black box warning following its investigation into secondary T-cell cancers arising from the use of existing CAR-T therapies.

Via Benzinga

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP)

January 16, 2024

AstraZeneca's stock rose 8.95% in the past month on a bullish outlook, driven by growing sales of cancer and diabetes drugs and a strategic acquisition

AstraZeneca: Rebound in 2024 with double-digit earnings growth

January 11, 2024

Via MarketBeat

January 08, 2024

With its sale to AstraZeneca, Gracell blazes exit trail for cash-challenged Chinese biotechs ↗

January 05, 2024

Key Takeaways: AstraZeneca will acquire Chinese cell therapy maker Gracell for up to $1.2 billion, representing an 86% premium to the company’s pre-announcement share price

Via Benzinga

Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024 ↗

January 05, 2024

Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.

Via Investor's Business Daily

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RayzeBio, Inc. (Nasdaq – RYZB), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Daseke, Inc. (Nasdaq – DSKE), Karuna Therapeutics, Inc. (Nasdaq – KRTX)

January 04, 2024

GRACELL BIOTECHNOLOGIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Gracell Biotechnologies Inc. - GRCL

December 31, 2023

From Kahn Swick & Foti, LLC

Via Business Wire

Week In Review: $1.7 Billion Collaboration Between Elpiscience And Astellas Is Final 2023 Deal ↗

December 31, 2023

Shanghai’s Elpiscience Biopharma has formed a $1.7 billion collaboration with Japan’s Astellas Pharma to develop a novel bispecific macrophage engager, ES019, along with an unspecified program....

Via Talk Markets

Stock Market Ending 2023 On High Note; Tesla, Drug M&A In Focus: Weekly Review ↗

December 29, 2023

The major indexes boast big annual gains with the Dow at record highs.

Via Investor's Business Daily

Topics Stocks

Investor Sentiment Improves; Dow Jumps Over 150 Points ↗

December 27, 2023

The CNN Money Fear and Greed index showed an increase in overall market sentiment, while the index remained in the "Extreme Greed" zone on Tuesday.

Via Benzinga

Topics Stocks

December 26, 2023

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 150 points on Tuesday. The Dow traded up 0.50% to 37,574.66 while the NASDAQ rose 0.50% to 15,068.50. The...

Nasdaq Surges 75 Points; Inspira Technologies Shares Spike Higher ↗

December 26, 2023

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

December 26, 2023

Via Benzinga

Why RayzeBio Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

December 26, 2023

Shares of RayzeBio, Inc. (NASDAQ: RYZB) rose sharply during Tuesday’s session after the company announced that it will be acquired by Bristol Myers Squibb for $62.50 per share in cash in a deal worth...

Via Benzinga

Crude Oil Rises Over 3%; US Home Prices Increase In October ↗

December 26, 2023

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 100 points on Tuesday. The Dow traded up 0.34% to 37,511.87 while the NASDAQ rose 0.43% to 15,057.13. The...

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

December 26, 2023

Via Benzinga

Why Sentage Holdings Shares Are Trading Lower By 5%; Here Are 20 Stocks Moving Premarket ↗

December 26, 2023

Shares of Sentage Holdings Inc. (NASDAQ: SNTG) shares moved lower in pre-market trading following results for the six months ended June 30, 2023.

Via Benzinga

US Stocks Set To Start Final Trading Week Of Year On Positive Note As Santa Claus Rally Gets Going: Analyst Confident Of Market Finishing Year At Highs ↗

December 26, 2023

Stocks appear on track to start Tuesday's session on a positive note amid positive expectations concerning interest rates and economy.

Via Benzinga

AstraZeneca Bolsters Cell Therapy Pipeline With Over $1B Deal For China-Based Gracell Biotechnologies ↗

December 26, 2023

AstraZeneca Plc (NASDAQ: AZN) has agreed to acquire Gracell Biotechnologies Inc (NASDAQ: GRCL), further strengthening AstraZeneca's cell therapy portfolio.

Via Benzinga

Gracell Biotechnologies, Stratasys, Hollysys Automation Technologies And Other Big Stocks Moving Higher In Tuesday's Pre-Market Session ↗

December 26, 2023

U.S. stock futures were higher this morning, with the Dow Jones futures gaining more than 40 points on Tuesday.

Via Benzinga

Topics Stocks

GRCL Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Gracell Biotechnologies Inc. Is Fair to Shareholders

December 26, 2023

From Halper Sadeh LLC

Via Business Wire

AstraZeneca to acquire Gracell, furthering cell therapy ambition across oncology and autoimmune diseases

December 26, 2023

From AstraZeneca

Via Business Wire

Gracell Biotechnologies to be acquired by AstraZeneca, furthering cell therapy ambition across oncology and autoimmune diseases

December 26, 2023